In vitro susceptibility of Sarcoptes scabiei var. hominis to 1% topical ivermectin
Keywords:
Scabies, Sarcoptes scabiei, mites, ivermectinAbstract
Objective The objective of this study was to measure the in-vitro susceptibility of Sarcoptes scabiei var. hominis to 1% w/v ivermectin.Methods This interventional (quasi-experimental) study was conducted in the OPD, Dermatology Department, Military Hospital, Rawalpindi from January 2013 to July 2013. A total of 40 mites were taken for assay. Extruded mites from every patient were placed in 1% ivermectin w/v over a glass slide. Mites were inspected for leg movements at hourly intervals. Death was declared once all leg movements had ceased. All mites which died within 5 hours were declared susceptible. The mites having active leg movements even after 5 hours of drug application were considered resistant. Results 100% (n=40) of mites died within 5 hours of application of 1% ivermectin, which was significant.Conclusion Topical 1% ivermectin is effective against Sarcoptes scabiei in terms of in vitro susceptibility.ÂReferences
Hicks MI, Elston DM. Scabies. Dermatol Ther. 2009;22:79-92.
Le Cleach L, Chosidow O. Commentary on "Interventions for treating scabies". Evid Based Child Health. 2011;6:1865-6.
Wolf R, Davidovici B. Treatment of scabies and pediculosis. Facts and controversies. Clin Dermatol. 2010; 28:511-18.
Christine KC, John R, Steven JS et al. Scabies surveillance, prevention and control. Ann Long Term Care. 2009;17:31-5.
Walton SF, Currie BJ. Problems in diagnosing scabies, global disease in human and animal populations. Clin Microbiol Rev. 2007;20:268-79.
Anwar IM, Rizvi SDA, Dilnawaz M et al. Comparison of in-vitro susceptibility of Sarcoptes scabiei var. hominis to 5% permethrin and 1% lindane. PAFMJ. In press 2014.
Pasay C, Arlian L, Morgan M et al. High-resolution melt analysis for the detection of a mutation associated with permethrin resistance in a population of scabies mites. Med Vet Entomol. 2008;22:82-8.
Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol. 2005;44:981-8.
Walton SF, Myerscough MR, Currie BJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg. 2000;94:92-6.
Mounsey KE, Holt DC, McCarthy J et al. Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. Future Microbiol. 2008;3:57-66.
Rizvi SDA, Iftikhar N, Batool F. Effectiveness of oral ivermectin for eradicating infesting mites in patients of scabies. J Pak Assoc Dermatol. 2011;21:87-92.
Ranjkesh MR, Naghili B, Goldust M, Rezaee E. The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies. Ann Parasitol. 2013;59:189-94.
Bachewar NP, Thawani VR, Mali SN et al. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol. 2009;41:9-14.
Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol. 2013;59:79-84.
Chhaiya SB, Patel VJ, Dave JN et al. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012;78:605-10.
Mushtaq A, Khurshid K, Pal SS. Comparison of efficacy and safety of oral ivermectin with topical permethrin in treatment of scabies. J Pak Assoc Dermatol. 2010;20:227-31.
Ribeiro Fde A, Taciro E, Guerra MR, Eckley CA. Oral ivermectin for the treatment and prophylaxis of scabies in prison. J Dermatolog Treat. 2005;16:138-41.
Victoria J, Trujillo R. Topical ivermectin: a new successful treatment for scabies. Pediatr Dermatol. 2001;18:63-5.
